cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Crispr Therapeutics Ag
242 own
88 watching
Current Price
$0
$4.93
(9.42%)
logo-crsp
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
4,094.71M
52-Week High
52-Week High
86.95
52-Week Low
52-Week Low
38.94
Average Volume
Average Volume
1.37M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
16.7148
iconMarket Capitalization4,094.71M
icon52-Week High86.95
icon52-Week Low38.94
iconAverage Volume1.37M
iconDividend Yield--
iconP/E Ratio16.7148
What does the Crispr Therapeutics Ag do?
CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Read More
How much money does Crispr Therapeutics Ag make?
News & Events about Crispr Therapeutics Ag.
Globe Newswire
22days ago
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to ...
Globe Newswire
1month ago
ZUG, Switzerland and BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head...
Globe Newswire
1month ago
-Update provided for both Part A (single dose with optional re-dosing) and Part B (consolidation dosing) of the Phase 1 CARBON clinical trial- -Part A data presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition confirm that CTX110 can lead to long-term durable ...
Business Wire
1month ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced an oral, encore presentation of clinical data from patients with sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT) treated with the investigational therapy exagamglogene...
Globe Newswire
2 months ago
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a ...
Frequently Asked Questions
Frequently Asked Questions
What is Crispr Therapeutics Ag share price today?
plus_minus_icon
Can Indians buy Crispr Therapeutics Ag shares?
plus_minus_icon
How can I buy Crispr Therapeutics Ag shares from India?
plus_minus_icon
Can Fractional shares of Crispr Therapeutics Ag be purchased?
plus_minus_icon
What are the documents required to start investing in Crispr Therapeutics Ag stocks?
plus_minus_icon
What is today’s traded volume of Crispr Therapeutics Ag?
plus_minus_icon
What is today’s market capitalisation of Crispr Therapeutics Ag?
plus_minus_icon
What is the 52-Week High and Low Range of Crispr Therapeutics Ag?
plus_minus_icon
What percentage is Crispr Therapeutics Ag down from its 52-Week High?
plus_minus_icon
What percentage is Crispr Therapeutics Ag up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$4.93
(9.42%)
logo-crsp
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00